GSK shares start to recover as firm refutes Zantac litigation claims
- Shares rally as group defends litigation claims- £9.9 billion hit to market value over two days- Analysts estimate risk to be $2 billionShares in pharmaceutical leviathan GSK plc (GSK) rallied 4.4% after management said it would...
12 August 2022